Short Interest in Entera Bio Ltd. (NASDAQ:ENTX) Decreases By 13.7%

Entera Bio Ltd. (NASDAQ:ENTX - Get Free Report) saw a large decline in short interest in March. As of March 15th, there was short interest totalling 86,100 shares, a decline of 13.7% from the February 28th total of 99,800 shares. Approximately 0.3% of the shares of the stock are short sold. Based on an average trading volume of 114,700 shares, the days-to-cover ratio is presently 0.8 days.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a "buy" rating and issued a $10.00 target price on shares of Entera Bio in a research report on Tuesday, March 18th.

Institutional Trading of Entera Bio

Several large investors have recently bought and sold shares of the business. Parkman Healthcare Partners LLC boosted its holdings in shares of Entera Bio by 2.4% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 411,076 shares of the company's stock worth $781,000 after purchasing an additional 9,558 shares during the last quarter. Perigon Wealth Management LLC acquired a new position in Entera Bio during the fourth quarter worth $325,000. Northern Trust Corp acquired a new position in Entera Bio during the fourth quarter worth $450,000. Finally, Knoll Capital Management LLC grew its holdings in Entera Bio by 51.5% in the 4th quarter. Knoll Capital Management LLC now owns 5,881,879 shares of the company's stock valued at $12,470,000 after buying an additional 2,000,000 shares in the last quarter. Hedge funds and other institutional investors own 14.11% of the company's stock.

Entera Bio Stock Up 0.3 %

Shares of NASDAQ ENTX traded up $0.01 during midday trading on Monday, hitting $1.61. The stock had a trading volume of 80,501 shares, compared to its average volume of 105,966. The stock has a 50 day simple moving average of $2.06 and a 200-day simple moving average of $2.01. The company has a market capitalization of $72.90 million, a PE ratio of -6.17 and a beta of 1.47. Entera Bio has a 1 year low of $1.41 and a 1 year high of $3.35.

Entera Bio (NASDAQ:ENTX - Get Free Report) last announced its earnings results on Friday, March 28th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.02. The business had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.04 million. As a group, analysts expect that Entera Bio will post -0.28 earnings per share for the current fiscal year.

About Entera Bio

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.